Unknown

Dataset Information

0

End-point immobilization of recombinant thrombomodulin via sortase-mediated ligation.


ABSTRACT: We report an enzymatic end-point modification and immobilization of recombinant human thrombomodulin (TM), a cofactor for activation of anticoagulant protein C pathway via thrombin. First, a truncated TM mutant consisting of epidermal growth factor-like domains 4-6 (TM(456)) with a conserved pentapeptide LPETG motif at its C-terminal was expressed and purified in E. coli. Next, the truncated TM(456) derivative was site-specifically modified with N-terminal diglycine containing molecules such as biotin and the fluorescent probe dansyl via sortase A (SrtA) mediated ligation (SML). The successful ligations were confirmed by SDS-PAGE and fluorescence imaging. Finally, the truncated TM(456) was immobilized onto an N-terminal diglycine-functionalized glass slide surface via SML directly. Alternatively, the truncated TM(456) was biotinylated via SML and then immobilized onto a streptavidin-functionalized glass slide surface indirectly. The successful immobilizations were confirmed by fluorescence imaging. The bioactivity of the immobilized truncated TM(456) was further confirmed by protein C activation assay, in which enhanced activation of protein C by immobilized recombinant TM was observed. The sortase A-catalyzed surface ligation took place under mild conditions and occurs rapidly in a single step without prior chemical modification of the target protein. This site-specific covalent modification leads to molecules being arranged in a definitively ordered fashion and facilitating the preservation of the protein's biological activity.

SUBMITTER: Jiang R 

PROVIDER: S-EPMC3310247 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

End-point immobilization of recombinant thrombomodulin via sortase-mediated ligation.

Jiang Rui R   Weingart Jacob J   Zhang Hailong H   Ma Yong Y   Sun Xue-Long XL  

Bioconjugate chemistry 20120308 3


We report an enzymatic end-point modification and immobilization of recombinant human thrombomodulin (TM), a cofactor for activation of anticoagulant protein C pathway via thrombin. First, a truncated TM mutant consisting of epidermal growth factor-like domains 4-6 (TM(456)) with a conserved pentapeptide LPETG motif at its C-terminal was expressed and purified in E. coli. Next, the truncated TM(456) derivative was site-specifically modified with N-terminal diglycine containing molecules such as  ...[more]

Similar Datasets

| S-EPMC6767613 | biostudies-literature
| S-EPMC5537000 | biostudies-literature
| S-EPMC4613866 | biostudies-literature
| S-EPMC2063460 | biostudies-literature
| S-EPMC6414994 | biostudies-literature
| S-EPMC3111449 | biostudies-literature
| S-EPMC7357393 | biostudies-literature
| S-EPMC5551486 | biostudies-other
| S-EPMC3490390 | biostudies-literature